(Q37688144)

22 August 2017

1 reference

title

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist (English)

1 reference

22 August 2017

Davide Capodanno

1

0 references

Dominick Angiolillo

series ordinal

3

object named as

Dominick J Angiolillo

1 reference

22 August 2017

Kodlipet Dharmashankar

series ordinal

2

1 reference

22 August 2017

1 February 2010

1 reference

Expert Review of Cardiovascular Therapy

22 August 2017

1 reference

22 August 2017

8

1 reference

22 August 2017

2

1 reference

22 August 2017

151-158

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Clinical overview of promising nonthienopyridine antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

ADP receptor antagonism: what's in the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Pharmacology of emerging novel platelet inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.172

21 January 2018

Identifiers

DOI

10.1586/ERC.09.172

1 reference

22 August 2017

1 reference

PubMed ID

20136601